Drug Delivery and Translational Research Update

DDTR First Impact Factor 1.887

We are pleased to announce the first DDTR impact factor (IF) of 1.887. This two-year IF is based on total number of citations in 2015 for the articles published in 2014 and 2013. The five-year IF is 1.917, which is the average number of times articles from the journal published in the past five years have been cited. Considering that DDTR began publishing in 2011 and the journal has been indexed recently (2015) in PubMed, a widely searched and used database, the first IF that the journal received is an important milestone. Since indexing in PubMed, we have noticed an increased number of citations. Compared with that in July 2015, the number of citations this year during the same time period has increased by 150%, and hence we anticipate that the 2016 IF of the journal will be higher. The average number of downloads per article from DDTR is around 250. The journal has also seen a greater than 70% increase in submissions compared with the previous year. With a merger between Nature Publishing Group, Palgrave Macmillan, Macmillan Education, and Springer Science+Business Media, DDTR is now a part of the newly formed Springer Nature. With that merger, DDTR is expected to reach an ever-growing multidisciplinary audience. Consider submitting your high-quality basic and clinical research and review articles for greater visibility and expanding your reach to the global community. Submit your best research or clinical article to compete for the 2016 DDTR Outstanding Research Paper Award. Visit the CRS website for further details. CRS members have free access to articles published in DDTR as a membership benefit. Visit the CRS website for instructions on how to download articles.

Special Issue Under Development: Late Stage Development of Drug Delivery Systems

This special issue will showcase emerging drug delivery approaches that have achieved significant milestones in clinical applications. Topics include various drug delivery systems and devices currently in clinical trials for both small and large molecules including proteins and genes, with a focus on their development strategies, drug product design, manufacturing insights, stability study design, lyophilization approaches, and targeted delivery approaches in both polymeric and lipid systems. Contact the guest editors if you wish to submit an article to this special issue: Keyur Gada (keyur.s.gada@gmail.com) and Vishwesh Patil (patil.vishwesh@gmail.com), Biogen, Cambridge, MA, U.S.A.

Special Issue: Advances in Technology and Business Potential of New Drug Delivery Systems (Volume 6, Issue 4, 2016)

This DDTR special issue materialized from the 14th international symposium of the CRS India Local Chapter on Advances in Technology and Business Potential of New Drug Delivery Systems, organized at the Institute of Chemical Technology, Mumbai, India. The issue encompasses an eclectic blend of review and research papers pertaining to different aspects of novel drug delivery. The issue gives insight into the upcoming strategies in novel drug delivery science that hold strong business opportunities to drive the pharmaceutical business.

About the Guest Editors

Vandana B. Patravale is a professor of pharmaceutics at the Department of Pharmaceutical Sciences and Technology of the Institute of Chemical Technology, Mumbai, India. She has over 100 refereed publications, 9 book chapters, 4 granted patents, 24 patents in the pipeline, and 3 trademark registries to her credit and has handled many national and international projects. She has worked in close collaboration with industry and holds an extensive experience of approximately 25 years in the field of pharmaceutical sciences and technology. Her areas of expertise include conventional and modified release dosage forms, formulation strategies to enhance bioavailability and/or targeting, medical device development (coronary stents, intrauterine devices), nanodiagnostics, and novel nanocarriers with major emphasis on malaria, cancer, and neurodegenerative disorders. She has published two books, Nanotechnology in Drug Delivery—A Perspective on Transition from Laboratory to Market from Woodhead Publishing (now Elsevier) and Pharmaceutical Product Development: Insights into Pharmaceutical Processes, Management and Regulatory Affairs from CRC Press (Taylor and Francis).

John I. Disouza is a professor in pharmaceutics and principal at Tatyasaheb Kore College of Pharmacy, Kolhapur, India. He has over 15 years of teaching and research experience. He also has an executive MBA (higher education) degree. He has written two books, Experimental Microbiology and Biotechnology and Fermentation Processes, and has published over 50 research papers in peer-reviewed journals. He has worked in diverse research areas including herbal formulations; micro/nanoparticulates; self-emulsifying, liposomal, fast, and modified release drug delivery systems; and so on. His research areas of interest are probiotics, novel diagnostic tools and therapies in cancer, and structural modifications of natural polymers for their pharmaceutical potential. He is an active consultant to the pharmaceutical industry.

Munira Momin is a professor and head of the Department of Pharmaceutics and currently serving as a principal (I/c) at SVKM’s Dr. Bhanuben Nanavati College of Pharmacy, Mumbai, India. She obtained her MPharm (pharmaceutics) from L.M. college of Pharmacy, Gujatat University, Ahmedabad, India. She received a gold medal (pharmaceutics) in her BPharm. Her PhD (pharmaceutical sciences) is on targeted drug delivery for phytoconstituents. She is a recipient of the Prof. M. L. Khurana Memorial Award for Best Research Paper published during the year 2008 in Pharmaceutics and Bio-Pharmaceutics. Her research interests include formulation approaches for effective wound healing, colon-targeted drug delivery systems, and nanotechnology-based drug delivery systems for the transdermal and mucosal routes. Her team is currently working on surface-engineered polymeric nanoparticles for brain targeting and cancer therapy. Dr. Momin has published several research papers in national and international journals with good impact factors and has patents based on nanotechnology in the pipeline. She has three books on pharmaceutics and pharmaceutical engineering to her credit. She has undertaken a number of industrial research projects. She is a reviewer for reputable journals from Elsevier and Bentham.